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Abstract: Disc degeneration plays a major role in this country’s medical, social and economic structure. The life-time 
prevalence of low back pain, which has disc degeneration as its cause, is about 80% in the general population. It is a pri-
mary cause of disability and estimated costs related to low back disorders exceed $100 billion per year in the U.S. alone. 
Biomarkers are becoming increasingly important as indicators of the presence of disease, and in evaluating outcomes dur-
ing clinical treatment. Cell-based biologic therapies which are currently being developed to treat disc degeneration are 
going to be most efﬁ  cacious when applied to the early stages of disc disease. In this article we ask: 1) Whether there are 
existing biomarkers which could play a role in detecting early stages of disc degeneration, and 2) Highlight exciting poten-
tials in future biomarker screening for disc degeneration. 
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Introduction
The NIH Biomarker Deﬁ  nitions Working Group has provided a very useful deﬁ  nition of a biomarker, 
describing it as “a characteristic that can be measured and evaluated as an indicator of normal biologic 
processes, pathologic processes or pharmacologic responses to therapeutic intervention” (Biomarkers 
Deﬁ  nitions Working Group, Bethesda, MD). The Working Group further stated that the use of biomarkers 
can be quite wide, including evaluation of efﬁ  cacy and safety (in either in vitro studies, in vivo animal 
studies, or early clinical trials), identiﬁ  cation of patients with a disease or abnormal condition, charac-
terization of disease stages, indicators of disease prognosis, and in monitoring the clinical response to 
a disease intervention.
Interest in biomarkers continues to expand today, with application of biomarker detection and 
measurement capabilities being channeled into practical diagnostic and therapeutic information 
modalities, and sensitive, speciﬁ  c biomarkers for early disease detection (Liszewski, 2006). Articles 
in the scientiﬁ  c press reﬂ  ect a general interest in biomarker applications in early drug development, 
and protein and pharmacodynamic and metabolomic biomarkers are being developed and marketed. 
Gene expression techniques have now been utilized in identiﬁ  cation of biomarkers, as shown by the
recent work by Laterze et al. suggesting discovery of potential new biomarkers for brain injury (Rifa 
et al. 2006; Laterza et al. 2006). Another novel approach to biomarker identiﬁ  cation was recently 
announced by Gustavson et al. from their work with measurement of the protein concentrations
of thymidylate synthase within speciﬁ  c cells and cell compartments in colorectal carcinomas 
(Gustavson, 2006). 
When single biomarkers cannot provide adequate information or speciﬁ  city, “biomarker proﬁ  les” 
or “biomarker panels” are now commonly being used, and for some diseases we now know that
early biomarkers for disease may differ from important biomarkers exhibited during later disease 
progression.
High Clinical Relevance of Disc Degeneration
Disc degeneration is a multifactorial process which is inﬂ  uenced by contributions from genetic predis-
position, lifestyle conditions (including obesity, occupation, smoking, alcohol consumption), other 
health factors (such as diabetes), and the aging phenomena. An understanding of the etiology and 
epidemiology of disc degeneration and low back pain, and of the operative and non-operative options 
available to the orthopaedic surgeon, are important factors which guide the surgeon in selection of the 
best treatment for the individual patient (Hanley and David, 1999).
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Disc degeneration is a chronic condition associ-
ated with morbidity and a signiﬁ  cant reduction in 
the quality of life for the patient. Although not 
lethal, the socioeconomic consequences of long-
term low back pain are high, and, as recently 
pointed out by Katz, the current estimate for the 
total costs of low back pain in the United States 
exceeds $100 billion per year (Katz, 2006). This 
startlingly high ﬁ  gure points to the critical impor-
tance of development of new strategies designed 
to prevent disc degeneration and low back pain. 
Many clinical investigators, including our group, 
feel that cell-based biologic therapies offer great 
potential for the treatment of disc degeneration 
(Gruber et al. 2006; Gruber et al. 2001; Gruber et al. 
2004). Such therapeutic modalities, which include 
disc cell augmentation, direction of adult mesen-
chymal stem cells to a disc-like phenotype, appli-
cation of growth factors/cytokines, and possibly 
gene therapy, will be most efﬁ  cacious when applied 
to the early stages of disc degeneration. Thus the 
potential application of biomarkers for early iden-
tiﬁ  cation of the patient at risk for disc degeneration 
and low back pain, is an important goal for today’s 
disc research lab. 
Disc Degeneration and Biomarkers
In late 2005, the NIH, the American Academy of 
Orthopaedic Surgeons and the Orthopaedic 
Research Society organized a workshop focused 
upon disc degeneration. The relevance of biologic 
markers of matrix formation and matrix turnover 
in the diagnosis of other musculoskeletal condi-
tions, such as osteoarthritis and osteoporosis, was 
discussion by Poole (Poole, 2006). Since that 
presentation, there is now new evidence that serum 
levels of hyaluronic acid show potential as a 
biomarker for osteoarthritis based on the ﬁ  ndings 
of Elliott et al. in the Johnston County Osteoar-
thritis Study (Elliott et al. 2005). However, the 
avascular nature of the adult disc presents a major 
block to the employment of the commonly used 
cartilage and bone biomarkers for studies of the 
disc. The number of blood vessels in the annulus 
and the number of vascular canals in the cartilage 
end plates decrease progressive during childhood 
(Taylor and Twomey, 1988) and are markedly 
diminished by age 3 years. By young adulthood, 
the disc is avascular and cellular nutrition relies on 
diffusion of solutes through the matrix via disc 
compression (Maroudas, 1988). 
 Balaguè et al. have recently carried out a study 
on the potential value of blood biomarkers in disc 
metabolism in patients with sciatica (Balagué et al. 
2006). Keratan sulfate, hyaluronan and cartilage 
oligomeric matrix protein (COMP) were tested for 
their utility as biomarkers. Their study found that 
a single measurement of these molecules did not 
have any diagnostic or therapeutic relevance in 
their subjects with acute radicular compression. 
All molecules showed an increase after their 
average 4.3 year follow-up.
 In another study, Yüceer et al. investigated the 
possibility of using changes in serum immuno-
globulin concentrations to assess lumbar disc 
disease (Yüceer et al. 2000). This study of IgG, 
IgA and IgM measurement found no signiﬁ  cant 
difference in serum levels of patients with disc 
disease compared to normal controls. 
Patients with herniated discs have been found 
to have increased concentrations of neuroﬁ  lament 
protein and S-100 in cerebrospinal ﬂ  uid (indicating 
possible damage of axons and Schwann cells in 
nerve roots) (Brisby et al. 1999); however, it is 
unlikely that cerebrospinal ﬂ  uid sampling would 
be a useful biomarker in the general population. 
Future Directions for Biomarkers 
for Early Disc Degeneration
In light of its public health importance, we suggest 
that research must continue in search of relevant, 
accurate and sensitive biomarkers of disc degen-
eration. MRI and radiographic imaging techniques 
certainly provide sensitive and accurate techniques 
for identiﬁ  cation of late-stage disc degeneration 
based upon the disc morphology images, disc 
height and hydration. To date, early changes 
cannot be detected with use of these routine meth-
odologies. 
New studies, however, point to exciting future 
possibilities for application of non-invasive T1ρ-
weighted magnetic resonance imaging (MRI) 
imaging techniques to detect each loss of proteo-
glycan in the nucleus of the disc (Johannessen
et al. 2005). Johannessen et al. found that T1ρ bore 
a better relationship to sulfated proteoglycans in 
the disc than did T2 imaging results. Other advan-
tages of the T1ρ methodology are that it does not 
require a contrast agent, it can be performed 
quickly, and provides a spatial map of proteoglycan 
content. Majumdar et al. also noted that in addition 
to the proteoglycan content, the T1ρ ﬁ  ndings are 
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also related to water content (Majumdar et al. 
2005). In their study, HR-MAS (spectroscopic) 
data correlated well with the Thompson grade for 
disc degeneration scoring (Thompson et al. 1990); 
the researchers also noted that an increase was 
found for levels of unbound hydroxyprolines and 
glycine in the annulus which was directly associ-
ated with collagen breakdown during disc 
degeneration.
Biomarkers which could be used to correlate 
the patient’s status with regard to pain, symptoms 
and prognosis would be especially valuable. Simi-
larly, imaging studies which might be able to be 
related to discogenic low back pain would clini-
cally be valuable to assess symptom severity. 
Although currently of more interest to researchers, 
biomarkers of pain might be of high value in early 
stages of disc degeneration when routine imaging 
studies are asymptomatic. 
In conclusion, we hope that we have shown 
the reader the exciting potentials which 
development of biomarkers for disc degeneration, 
especially disc degeneration in its early stages, 
holds for the future. Important summary points 
are that:
   Disc degeneration poses large heath care and 
socio-economic costs.
   Future cell-based biologic therapies hold great 
promise for disc degeneration, and may be most 
useful in cases of early disc degeneration.
   Thus identification and development of 
sensitive and accurate biomarkers for early 
disc degeneration is an important health care 
goal.
   Serum and urine biomarkers—which work well 
for osteoarthritis and metabolic bone diseases 
such as osteoporosis and Paget’s disease – need 
to be investigated for disc degeneration bio-
markers; however such assays may have lim-
ited applicability because of the avascular nature 
of the adult human disc.
   Newly developed advances in MRI imaging, 
which can quantitatively assess tissue hydration 
in the disc (such as T1ρ) and spectroscopic 
(HRMAS) methods currently hold exciting 
promise for useful, non-invasive biomarkers of 
early disc degeneration.
   Development of future biomarkers for disco-
genic pain, and study of their correlation with 
severity of symptoms and new imaging results, 
also holds great promise.
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